Russia has begun clinical trials to determine the efficacy of the COVID-19 Sputnik V vaccine in adolescents, the Health Ministry reported.
The permit issued for the tests includes about 660 people between the ages of 12 and 17, said Leila Namzova-Baranova, head of preventive medicine in children at the Ministry of Health, according to the TASS agency.
The first and second phase trials will take place in two Moscow hospitals, she added.
The deputy mayor of Moscow, Anastasia Rákova, said that the tests have already started in the Russian capital in collaboration with the Gamaleya Center, developer of the vaccine.
According to Rákova, about a hundred people have already been selected for the tests, which will last about a year and in which lower doses of Sputnik V will be used than for adults.
The third phase will begin in late summer and will include about 250 teenagers, according to the Interfax agency.
There are currently four vaccines in Russia: Sputnik V, the Sputnik Light single-dose, EpiVacCorona and CoviVac, although it is the first one that is used so far mainly to vaccinate the population in the country.
So far, 25.1 million people or 17.19% of the population have been vaccinated, according to the Gogov.ru page, the only one that, in the absence of regular official data, publishes updated information by region.
The epidemic situation in Russia is tense, since it has registered between 24,000 and 25,000 daily cases and maximum deaths in recent days.
In the last day, the country has reported 24,353 new infections and 654 deaths from the disease.
Most of the new positives were detected in Moscow (6,557), in Moscow province (2,651) and in Saint Petersburg (1,828).
Russia is the fifth country with the most coronavirus cases (5,635,294) in the world followed by the US, India, Brazil and France.